CIK 0001348911
KALV KalVista Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Sep 9, 2025. Close $27.00 on Jun 10, 2026, 0% from the 52-week low and 0% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at KalVista Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $116k 7,294 shares | -2% | - | |
| 20Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $31k 2,336 shares | -2% | - | |
| 20Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $26k 1,954 shares | -1% | - | |
| 15Weak | Nicole Sweeny Chief Commercial Officer sell | $20k 1,480 shares | -4% | - | |
| 21Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $39k 2,942 shares | -2% | - | |
| 36Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $145k 10,940 shares | -3% | - | |
| 20Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $31k 2,362 shares | -2% | - | |
| 15Weak | Nicole Sweeny Chief Commercial Officer sell | $25k 1,864 shares | -6% | - | |
| 21Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $39k 2,939 shares | -2% | - | |
| 32Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $58k 4,409 shares | -1% | - | |
| 21Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $35k 2,649 shares | -2% | - | |
| 45Moderate | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $475k 30,250 shares | -19% | - | |
| 51Moderate | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $518k 32,979 shares | -8% | - | |
| 20Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $104k 7,169 shares | -2% | - | |
| 15Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $24k 2,146 shares | -2% | - | |
| 15Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $22k 1,926 shares | -2% | - | |
| 20Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $32k 2,689 shares | -2% | - | |
| 35Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $119k 9,999 shares | -3% | - | |
| 20Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $28k 2,317 shares | -2% | - | |
| 21Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $33k 2,776 shares | -3% | - | |
| 31Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $45k 3,808 shares | -1% | - | |
| 20Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $31k 2,600 shares | -3% | - | |
| 20Weak | Venrock Healthcare Capital Partners III, L.P. owner buy | $236k 25,000 shares | +0% | - | |
| 34Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $80k 6,669 shares | -2% | - | |
| 15Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $24k 2,394 shares | -2% | - | |
| 15Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $19k 1,918 shares | -2% | - | |
| 20Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $31k 3,125 shares | -3% | - | |
| 32Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $50k 5,104 shares | -2% | - | |
| 20Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $26k 2,601 shares | -3% | - | |
| 37Weak | Venrock Healthcare Capital Partners III, L.P. owner buy | $1.5M 161,700 shares | +3% | - | |
| 37Weak | Venrock Healthcare Capital Partners III, L.P. owner buy | $967k 104,489 shares | +2% | - | |
| 27Weak | Venrock Healthcare Capital Partners III, L.P. owner buy | $622k 70,023 shares | +1% | - | |
| 33Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $74k 7,627 shares | -3% | - | |
| 15Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $22k 2,187 shares | -2% | - | |
| 15Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $19k 1,963 shares | -2% | - | |
| 23Weak | Paul K. Audhya CHIEF MEDICAL OFFICER sell | $75k 8,077 shares | -8% | - | |
| 23Weak | Christopher Yea CHIEF DEVELOPMENT OFFICER sell | $67k 7,192 shares | -7% | - | |
| 36Weak | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER sell | $133k 14,400 shares | -5% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 6, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +15,625 | - | - | 402,483 | Sep 9, 2025 |
| Sep 8, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -7,294 | $15.84 | $116k | 395,189 | Sep 9, 2025 |
| Sep 6, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -15,625 | $0.00 | $0 | 156,251 | Sep 9, 2025 |
| Aug 22, 2025 | Nicole Sweeny Chief Commercial Officer | MOption exercise Common Stock | +5,000 | - | - | 33,771 | Aug 26, 2025 |
| Aug 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +5,000 | - | - | 124,841 | Aug 26, 2025 |
| Aug 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +3,125 | - | - | 134,006 | Aug 26, 2025 |
| Aug 25, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -1,954 | $13.42 | $26k | 132,052 | Aug 26, 2025 |
| Aug 25, 2025 | Nicole Sweeny Chief Commercial Officer | SOpen-market sale Common Stock | -1,480 | $13.42 | $20k | 32,291 | Aug 26, 2025 |
| Aug 25, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,336 | $13.42 | $31k | 122,505 | Aug 26, 2025 |
| Aug 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 55,000 | Aug 26, 2025 |
| Aug 22, 2025 | Nicole Sweeny Chief Commercial Officer | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 55,000 | Aug 26, 2025 |
| Aug 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -3,125 | $0.00 | $0 | 34,375 | Aug 26, 2025 |
| Aug 21, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +23,250 | - | - | 397,798 | Aug 25, 2025 |
| Aug 21, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +6,250 | - | - | 122,783 | Aug 25, 2025 |
| Aug 21, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +3,750 | - | - | 133,243 | Aug 25, 2025 |
| Aug 21, 2025 | Nicole Sweeny Chief Commercial Officer | MOption exercise Common Stock | +6,250 | - | - | 30,635 | Aug 25, 2025 |
| Aug 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,942 | $13.22 | $39k | 119,841 | Aug 25, 2025 |
| Aug 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -2,362 | $13.22 | $31k | 130,881 | Aug 25, 2025 |
| Aug 22, 2025 | Nicole Sweeny Chief Commercial Officer | SOpen-market sale Common Stock | -1,864 | $13.22 | $25k | 28,771 | Aug 25, 2025 |
| Aug 22, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -10,940 | $13.22 | $145k | 386,858 | Aug 25, 2025 |
| Aug 21, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 87,500 | Aug 25, 2025 |
| Aug 21, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -23,250 | $0.00 | $0 | 325,500 | Aug 25, 2025 |
| Aug 21, 2025 | Nicole Sweeny Chief Commercial Officer | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 87,500 | Aug 25, 2025 |
| Aug 21, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 52,500 | Aug 25, 2025 |
| Aug 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +4,203 | - | - | 132,142 | Aug 19, 2025 |
| Aug 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +6,446 | - | - | 119,472 | Aug 19, 2025 |
| Aug 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +9,362 | - | - | 378,957 | Aug 19, 2025 |
| Aug 18, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,939 | $13.19 | $39k | 116,533 | Aug 19, 2025 |
| Aug 18, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -4,409 | $13.19 | $58k | 374,548 | Aug 19, 2025 |
| Aug 18, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -2,649 | $13.19 | $35k | 129,493 | Aug 19, 2025 |
| Aug 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -2,418 | $0.00 | $0 | 7,257 | Aug 19, 2025 |
| Aug 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -1,773 | $0.00 | $0 | 5,322 | Aug 19, 2025 |
| Aug 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -2,418 | $0.00 | $0 | 7,257 | Aug 19, 2025 |
| Aug 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -6,944 | $0.00 | $0 | 6,945 | Aug 19, 2025 |
| Aug 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -2,430 | $0.00 | $0 | 2,431 | Aug 19, 2025 |
| Aug 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -4,028 | $0.00 | $0 | 4,028 | Aug 19, 2025 |
| Aug 11, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | AGrant or award Restricted Stock Unitderivative | +113,920 | $0.00 | $0 | 113,920 | Aug 13, 2025 |
| Aug 11, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | AGrant or award Employee Stock Optionderivative | +113,920 | $0.00 | $0 | 113,920 | Aug 13, 2025 |
| Jul 8, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | AGrant or award Common Stock | +60,000 | - | - | 158,189 | Jul 10, 2025 |
| Jul 8, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +87,500 | - | - | 402,574 | Jul 10, 2025 |
| Jul 9, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -30,250 | $15.69 | $475k | 127,939 | Jul 10, 2025 |
| Jul 9, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -32,979 | $15.69 | $518k | 369,595 | Jul 10, 2025 |
| Jun 6, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +15,625 | - | - | 322,243 | Jun 10, 2025 |
| Jun 9, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -7,169 | $14.50 | $104k | 315,074 | Jun 10, 2025 |
| Jun 6, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -15,625 | $0.00 | $0 | 171,876 | Jun 10, 2025 |
| May 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +5,000 | - | - | 115,172 | May 27, 2025 |
| May 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +3,125 | - | - | 100,115 | May 27, 2025 |
| May 23, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,146 | $11.31 | $24k | 113,026 | May 27, 2025 |
| May 23, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -1,926 | $11.31 | $22k | 98,189 | May 27, 2025 |
| May 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 60,000 | May 27, 2025 |
| May 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -3,125 | $0.00 | $0 | 37,500 | May 27, 2025 |
| May 21, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +6,250 | - | - | 112,861 | May 23, 2025 |
| May 21, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +23,250 | - | - | 316,617 | May 23, 2025 |
| May 21, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +3,750 | - | - | 99,307 | May 23, 2025 |
| May 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,689 | $11.88 | $32k | 110,172 | May 23, 2025 |
| May 22, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -9,999 | $11.88 | $119k | 306,618 | May 23, 2025 |
| May 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -2,317 | $11.88 | $28k | 96,990 | May 23, 2025 |
| May 21, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -6,250 | $0.00 | $0 | 93,750 | May 23, 2025 |
| May 21, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -23,250 | $0.00 | $0 | 348,750 | May 23, 2025 |
| May 21, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -3,750 | $0.00 | $0 | 56,250 | May 23, 2025 |
| May 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +6,447 | - | - | 109,387 | May 20, 2025 |
| May 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +9,364 | - | - | 297,175 | May 20, 2025 |
| May 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +4,205 | - | - | 98,157 | May 20, 2025 |
| May 19, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,776 | $11.84 | $33k | 106,611 | May 20, 2025 |
| May 19, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -3,808 | $11.84 | $45k | 293,367 | May 20, 2025 |
| May 19, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -2,600 | $11.84 | $31k | 95,557 | May 20, 2025 |
| May 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 9,675 | May 20, 2025 |
| May 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 9,675 | May 20, 2025 |
| May 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -1,774 | $0.00 | $0 | 7,095 | May 20, 2025 |
| May 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -4,028 | $0.00 | $0 | 8,056 | May 20, 2025 |
| May 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -6,945 | $0.00 | $0 | 13,889 | May 20, 2025 |
| May 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -2,431 | $0.00 | $0 | 4,861 | May 20, 2025 |
| Apr 9, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +25,000 | $9.42 | $236k | 5,303,985 | Apr 11, 2025 |
| Mar 6, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +15,625 | - | - | 294,480 | Mar 10, 2025 |
| Mar 7, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -6,669 | $11.97 | $80k | 287,811 | Mar 10, 2025 |
| Mar 6, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -15,625 | $0.00 | $0 | 187,501 | Mar 10, 2025 |
| Feb 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +5,000 | - | - | 105,334 | Feb 25, 2025 |
| Feb 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +3,125 | - | - | 95,870 | Feb 25, 2025 |
| Feb 21, 2025 | Brian Piekos Chief Financial Officer | AGrant or award Restricted Stock Unitderivative | +80,000 | $0.00 | $0 | 80,000 | Feb 25, 2025 |
| Feb 21, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | AGrant or award Restricted Stock Unitderivative | +372,000 | $0.00 | $0 | 372,000 | Feb 25, 2025 |
| Feb 24, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -2,394 | $10.02 | $24k | 102,940 | Feb 25, 2025 |
| Feb 24, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -1,918 | $10.02 | $19k | 93,952 | Feb 25, 2025 |
| Feb 21, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Feb 25, 2025 |
| Feb 21, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | AGrant or award Restricted Stock Unitderivative | +60,000 | $0.00 | $0 | 60,000 | Feb 25, 2025 |
| Feb 22, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 65,000 | Feb 25, 2025 |
| Feb 22, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -3,125 | $0.00 | $0 | 40,625 | Feb 25, 2025 |
| Feb 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +6,447 | - | - | 103,459 | Feb 19, 2025 |
| Feb 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +9,363 | - | - | 283,959 | Feb 19, 2025 |
| Feb 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Common Stock | +4,204 | - | - | 95,346 | Feb 19, 2025 |
| Feb 18, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock | -3,125 | $9.82 | $31k | 100,334 | Feb 19, 2025 |
| Feb 18, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -5,104 | $9.82 | $50k | 278,855 | Feb 19, 2025 |
| Feb 18, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -2,601 | $9.82 | $26k | 92,745 | Feb 19, 2025 |
| Feb 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 12,094 | Feb 19, 2025 |
| Feb 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -2,419 | $0.00 | $0 | 12,094 | Feb 19, 2025 |
| Feb 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -1,774 | $0.00 | $0 | 8,869 | Feb 19, 2025 |
| Feb 17, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | MOption exercise Restricted Stock Unitderivative | -4,028 | $0.00 | $0 | 12,084 | Feb 19, 2025 |
| Feb 17, 2025 | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitderivative | -6,944 | $0.00 | $0 | 20,834 | Feb 19, 2025 |
| Feb 17, 2025 | Christopher Yea CHIEF DEVELOPMENT OFFICER | MOption exercise Restricted Stock Unitderivative | -2,430 | $0.00 | $0 | 7,292 | Feb 19, 2025 |
| Feb 12, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +100,000 | $9.23 | $923k | 5,217,285 | Feb 14, 2025 |
| Feb 13, 2025 | Venrock Healthcare Capital Partners III, L.P. owner | POpen-market purchase Common Stockindirect: By Funds | +61,700 | $9.33 | $576k | 5,278,985 | Feb 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Paul K. AudhyaCHIEF MEDICAL OFFICER
- Benjamin L PalleikoCHIEF EXECUTIVE OFFICER
- Brian PiekosChief Financial Officer
- Nicole SweenyChief Commercial Officer
- Venrock Healthcare Capital Partners III, L.P.owner
- Christopher YeaCHIEF DEVELOPMENT OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.